Max Healthcare Institute Limited (MAXHEALTH)

Healthcare · Healthcare Services · NSE · Updated 3 August 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹1,100.4 ↓ 11.69% (1Y)

🎯 Key Takeaways

  • Max Healthcare Institute Limited is in a strategic expansion phase, actively investing in infrastructure and hospital capacity to drive long-term growth in India's healthcare services sector. Management is focused on scaling operations through acquisitions and new hospital developments, reinforcing its position as a key player in the industry.
  • Revenue grew 9.4% QoQ to ₹1,868 in Q3FY25.
  • ⚠️ Ongoing litigation related to the Kalinga Hospital acquisition introduces execution and regulatory uncertainty, with a pending NCLT decision scheduled
Market Cap
₹1.02 L Cr
P/E Ratio
101.2
Div Yield
0.00%
Promoter
0.0%

📖 The Story

Max Healthcare Institute Limited is in a strategic expansion phase, actively investing in infrastructure and hospital capacity to drive long-term growth in India's healthcare services sector. Management is focused on scaling operations through acquisitions and new hospital developments, reinforcing its position as a key player in the industry.

📰 What's Happening

At the 25th Annual General Meeting on July 30, 2026, shareholders approved the audited standalone and consolidated financial statements for FY2025-26 and declared a final dividend of ₹2 per share. Chairman Abhay Soi highlighted ongoing expansion into new hospitals, the acquisition of Kalinga Hospital, and investments in medical technology and infrastructure, with plans to nearly double bed capacity over the next five years. However, litigation involving the Kalinga Hospital acquisition remains unresolved, with the National Company Law Tribunal adjourning the matter to August 4, 2026, introducing execution risk. The company continues to emphasize sustainable growth, ESG compliance, and governance oversight through dedicated committees.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricQ4FY23Q1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25
Revenue1,2151,2851,3631,3351,4231,5431,7071,868
Operating Profit381379433432427422491459
OPM %28.0%26.3%28.4%28.9%26.8%25.1%26.4%26.7%
Net Profit251240277289252236282239
EPS₹2.59₹2.47₹2.85₹2.98₹2.59₹2.43₹2.90₹2.46

Revenue has shown consistent growth over the past eight quarters, rising from ₹1,215 crore in Q4FY23 to ₹1,868 crore in Q3FY25, reflecting successful expansion and increased patient volume. Operating margins have remained stable around 26-28%, indicating disciplined cost management despite scaling operations. Net profit and EPS have fluctuated slightly but remain on an upward trend, with Q3FY25 NP at ₹239 crore and EPS at ₹2.46, supported by operational efficiency and revenue growth. The upward revenue trajectory aligns with management's stated strategy of capacity expansion and service line diversification.

🔮 Management Outlook & What's Next

During the AGM on July 30, 2026, management reaffirmed its long-term growth strategy, targeting nearly double the current bed capacity over the next five years through hospital expansions and strategic acquisitions. While no formal financial guidance was provided in the filings, management emphasized continued investment in infrastructure and medical technology to capture demand growth in Tier 1 and Tier 2 cities. The company also underscored its focus on ESG integration and sustainable operations as part of its governance framework, though forward-looking statements remain high-level without specific revenue or margin targets.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company MCap (₹ Cr) P/E ROCE ROE D/E
Apollo Hospitals Enterprise Limited 1.16 L Cr 64.5 20.5% 21.9% 0.64
Max Healthcare Institute Limited 1.02 L Cr 101.2
Fortis Healthcare Limited 72,752 94.6
Aster DM Healthcare Limited 39,048 7.1
Narayana Hrudayalaya Ltd. 37,625 47.7
Global Health Limited 33,405 65.8
Krishna Institute of Medical Sciences Limited 30,477 80.3
Dr. Lal Path Labs Ltd. 26,871 63.6
Syngene International Limited 18,295 36.3
Dr. Agarwal's Health Care Limited 14,266 88.8 14.9% 6.8% 0.13

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Ongoing litigation related to the Kalinga Hospital acquisition introduces execution and regulatory uncertainty, with a pending NCLT decision scheduled for August 4, 2026. 2. Rapid expansion through acquisitions and greenfield projects carries integration and execution risks, including potential delays or cost overruns. 3. High valuation multiples (P/E of 101.2) imply market expectations are priced in, leaving limited upside unless growth materializes as anticipated. 4. ESG and sustainability commitments, while strategically important, may increase operational and compliance costs without immediate financial returns.

📋 Recent Filings

🧠 Analyst's Read

Max Healthcare is executing a clear expansion strategy with visible revenue growth, but the pace and success of its hospital acquisition program — particularly the Kalinga Hospital deal — remain contingent on legal resolution and integration execution. Investors should monitor the August 2026 NCLT ruling and updates on capital allocation toward new facilities, as these will be critical inflection points for the company's growth trajectory.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-03.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MAXHEALTH files new disclosures

Track MAXHEALTH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MAXHEALTH — Free

Free account · 2 AI queries/day